Immix Biopharma (IMMX) Stock Soars Amidst New Clinical Trial Site Announcement
Immix Biopharma, Inc. (NASDAQ: IMMX) witnessed a notable surge in the valuation of its equities, marking an uptick of 10.95%, culminating in a closing price of $3.04 in the most recent trading session. This upward trajectory in Immix Biopharma’s stock was precipitated by the revelation of a prominent cancer center joining as a new trial […]
